Pfizer to seek re-examination of Xeljanz following negative opinion

The company said the recent development in the EU does not change the status of Xeljanz as an approved treatment option in the markets. The company feels compelled to address the risk benefit issue raised in the process although the reversal of such an opinion is not common. Comments taken form Q1 earnings conference.

View Comments (0)